Profound Medical (PROF) Q2 2026 earnings review
Growth Optically Masks Underlying Leverage; H2 Execution Ramp Looms Large
Profound Medical reported 12% YoY revenue growth to $2.5 million in Q2, heavily missing its momentum narrative on paper. However, this was entirely driven by a $3.1 million shipment bottleneck that slipped into July. Adjusted for this logistics delay, revenue would have accelerated 153% YoY to $5.6 million. The real story is the operating leverage: gross margins expanded to a record 78%, and operating expenses were slashed by 16%, shrinking net loss by 39%. While the company reiterated its $25.0 million FY26 guidance, achieving it requires a massive $17.2 million execution in the second half of the year.
🐂 Bull Case
Gross margin reached 78% in Q2, well above the 70% long-term target. Combined with a 16% YoY reduction in OpEx, Profound is proving its business model can scale profitably once critical mass is reached.
The company generated a record >$7.0 million in new purchase orders during Q2. The revenue miss was purely a shipping timing issue that has already been resolved in July.
🐻 Bear Case
Despite narrative of accelerating momentum, the TULSA INDEX20 (same-store utilization) dropped sequentially from 11.3 procedures per quarter in Q1 to 10.0 in Q2.
With only $7.8 million in H1 revenue, reiterating $25.0 million guidance means Profound must deliver $17.2 million in H2. Any further supply chain hiccups will guarantee a guidance miss.
⚖️ Verdict: ⚪
Neutral. The underlying demand and margin expansion are highly impressive, but operational bottlenecks and a slowing same-store utilization metric introduce significant execution risk for the ambitious H2 guidance.
Key Themes
Margin Expansion and Operating Leverage
Accelerating. Gross margin expanded from 73% in 25Q2 to 78% in 26Q2, reflecting a highly favorable product mix. Even better, operating expenses declined 16% YoY to $13.0 million due to lower personnel and post-CAPTAIN trial costs. This discipline drove a 39% improvement in net loss YoY, demonstrating a tangible path to profitability.
Macro Tailwind: Broadening Reimbursement Coverage
Stable. U.S. healthcare reimbursement macro-dynamics are turning heavily in Profound's favor. Payer coverage expanded by 18.3 million lives in Q2, primarily driven by state Medicaid and managed Medicaid programs. Furthermore, securing the Johns Hopkins and Prime Healthcare employee health plans marks a critical breakthrough into employer-owned networks.
Clinical Innovation: Penile Length Preservation
Accelerating. New post-market CAPTAIN Level 1 data presented in July showed statistically significant advantages of the TULSA Procedure over robotic radical prostatectomy in penile length preservation. This is a highly sensitive quality-of-life metric for patients and serves as a powerful new marketing tool for urologists to drive patient demand.
Logistics Bottlenecks Threaten Execution
Reversing. In 25Q4, management waved off concerns about scaling their supply chain, stating they were actively preparing for growth. The $3.1 million Q2 shipment delay validates those earlier fears. While characterized as a 'temporary logistics issue', failing to ship ~55% of the quarter's expected revenue by quarter-end highlights severe operational fragility.
TULSA INDEX20 Utilization Stalls
Reversing. Management touted 'accelerating commercial momentum', yet their own same-store sales tracker contradicts this. The TULSA INDEX20 dropped sequentially from 11.3 procedures in Q1 to 10.0 in Q2. While up YoY, a 12% QoQ drop in same-store utilization across mature sites is a red flag that demands an explanation.
Cash Runway Getting Tight
Decelerating. Cash and equivalents fell from $59.7 million at the end of FY25 to $38.3 million at the end of 26Q2. With $19.9 million burned in operating cash flow over just six months, the runway is narrowing. Unless the H2 revenue ramp translates immediately to positive cash flow, a dilutive capital raise is highly probable within the next 12 months.
Other KPIs
Accelerating. A new quarterly record, serving as the strongest leading indicator that the $2.5M reported revenue was purely optical. This robust backlog ensures a very strong baseline for Q3.
Stable. The pipeline for TULSA-PRO and Sonalleve within the 'Verify, Negotiate and Contracting' stages remains massive compared to the company's current run rate, validating the long-term demand story.
Guidance
Accelerating. Management reiterated their full-year guidance, which implies 56% YoY growth. However, with only $7.8 million booked in H1, they must deliver $17.2 million in H2. This requires back-to-back record quarters, leaving zero margin for error in sales cycle timing or supply chain logistics.
Stable. With Q2 coming in at 78%, achieving the full-year >70% target appears highly de-risked, provided capital system conversions do not require aggressive discounting.
Key Questions
Supply Chain Resilience
What was the exact nature of the 'logistics issue' that delayed $3.1M in shipments, and what specific operational changes have been made to ensure the supply chain can handle the steep $17.2M H2 revenue ramp?
TULSA INDEX20 Sequential Drop
Despite record order activity, same-store utilization across the INDEX20 cohort dropped 12% sequentially from Q1 to Q2. Was this driven by seasonality, staffing shortages at hospitals, or a normalization of backlogged demand?
Capital Requirements
With $38.3 million in cash and nearly $20 million in H1 operating burn, at what cash threshold would management look to tap the equity markets or draw on alternative financing to protect the balance sheet?